Vijayakumar Gayathri, Vance Dylan, Colman Matthew W, Gitelis Steven, Sweeney Kyle, Blank Alan T
Department of Orthopedic Surgery, Section of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois. ORCID: https://orcid.org/0000-0001-7324-4864.
University of Kansas Medical Center, Kansas City, Kansas.
J Opioid Manag. 2023 Sep-Oct;19(5):395-402. doi: 10.5055/jom.0813.
To investigate post-operative opioid use following a total hip arthroplasty (THA) in metastatic bone disease (MBD) patients and identify factors associated with post-operative opioid use at 6 weeks and 90 days.
MBD commonly affects the hip, and surgical intervention including THA may be indicated for pain relief or to improve function. Following THA, patients are often prescribed short courses of opioids for post-operative pain relief. No study has evaluated opiate use following THA in patients for MBD.
This was a retrospective review of patients using opioids preoperatively who underwent primary THA for MBD at two institutions between 2009 and 2022. Preoperative and post-operative opioid usages, respectively, at 6 weeks and 90 days were quantified through calculating daily morphine milligram equivalents (MMEs) and compared using the sign test. Factors associated with post-operative opioid use at 6 weeks and 90 days were compared using χ2 test or Fisher's exact test as appropriate.
Nineteen THA and 11 THA with complex acetabular reconstruction were included. At 6 weeks, 26 (86.7 percent) patients were utilizing opiates, and at 90 days, 23 (76.7 percent) patients were utilizing opiates. There was a statistically significant difference between median daily preoperative MME compared to daily MME at 90 days (p < 0.001). The only statistically significant association with opioid use at 90 days was opioid use at 6 weeks.
To our knowledge, this is the first paper evaluating post-operative opioid use following primary THA in MBD patients. After THA in the setting of MBD, patients exhibit decreased post-operative opioid use. Future studies with larger cohorts should be conducted to characterize post-operative opioid use following joint arthroplasty in MBD patients.
研究转移性骨病(MBD)患者全髋关节置换术(THA)后的术后阿片类药物使用情况,并确定与术后6周和90天时阿片类药物使用相关的因素。
MBD常累及髋关节,包括THA在内的手术干预可能用于缓解疼痛或改善功能。THA术后,患者常被开具短期阿片类药物用于术后止痛。尚无研究评估MBD患者THA后的阿片类药物使用情况。
这是一项对2009年至2022年间在两家机构接受MBD初次THA的术前使用阿片类药物患者的回顾性研究。通过计算每日吗啡毫克当量(MME)分别对术前和术后6周及90天的阿片类药物使用情况进行量化,并使用符号检验进行比较。使用χ2检验或Fisher精确检验(视情况而定)比较与术后6周和90天阿片类药物使用相关的因素。
纳入了19例THA和11例复杂髋臼重建的THA。在6周时,26例(86.7%)患者使用阿片类药物,在90天时,23例(76.7%)患者使用阿片类药物。术前每日MME中位数与90天时每日MME之间存在统计学显著差异(p < 0.001)。与90天阿片类药物使用唯一具有统计学显著关联的是6周时的阿片类药物使用。
据我们所知,这是第一篇评估MBD患者初次THA术后阿片类药物使用情况的论文。在MBD背景下进行THA后,患者术后阿片类药物使用减少。应开展更大样本量的未来研究,以描述MBD患者关节置换术后的阿片类药物使用情况。